hello I'm Tim Draper's digital twin join me on Draper decentralized for industry tips updates from my portfolio companies and insights into cuttingedge Innovation shaping our future Verge genomics has announced that Eli Lily and Company will pursue the development of Therapeutics for amyotrophic lateral sclerosis based on two Targets identified by verge's AI powered converge platform this collaboration which began in July 2021 resulted in verge's converge platform validating ALS targets at a rate of 83% significantly higher than industry standards as part of the agreement Verge has received near-term Milestone payments from Lily with the potential for additional
Downstream royalties as the programs Advance verg's Chief scientific officer Robert H scannan emphasized the value of their platform in advancing ALS research while Lily's doct Michael Hutton praised the scientific strength of verge's Target predictions Verge also continues to develop its internal ALS drug candidate vrg 50635 which is currently in a phase 1B study across multiple countries this achievement highlights verge's commitment to using AI to unlock new insights for treating ALS and other complex diseases thank you for watching today's dra Draper decentralized for more content that Sparks creativity and ignites entrepreneurial Spirit visit Draper tv.com [Music]
